Immune recovery and T cell subset analysis during effective treatment with maraviroc
Immune recovery and T cell subset analysis during effective treatment with maraviroc
复制标题
DOI：
10.1093/jac/dks216
复制
发表时间：
2012-10-01
影响因子：
5.2
通讯作者：
Nozza, Silvia
中科院分区：
文献类型：
--
作者：
Cossarini, Francesca;Galli, Andrea;Nozza, Silvia
使用马拉维洛克治疗的患者经常出现CD4 T细胞增高。本研究的目的是详细介绍马拉韦洛克诱导的免疫恢复的特点。我们研究了接受雷替格拉韦、依曲维林和马拉韦洛克（REM, n24）或达那韦/利托那韦（RED, n17）治疗的患者冷冻外周血单个核细胞的T细胞亚群。两组的活化CD4和CD8 T细胞的减少相似。在REM患者中观察到更大的初始CD4 T细胞损失和表达CXCR4的细胞减少，而RED患者表现出更大的表达CCR5的细胞损失。我们的发现不支持激活T细胞亚群减少的作用来解释更大的马拉韦洛克诱导的免疫恢复。CXCR4CD4的减少和CCR5CD4 T细胞的高表达可能代表了对非r5热带病毒株过度生长的潜在保护。
Patients treated with maraviroc frequently show high CD4 T cell increases. The aim of this study was to detail the characteristics of maraviroc-induced immune recovery.We studied T cell subsets from frozen peripheral blood mononuclear cells of patients treated with raltegravir, etravirine and either maraviroc (REM, n24) or darunavir/ritonavir (RED, n17).The two groups showed a similar decrease in activated CD4 and CD8 T cells. A greater loss of naive CD4 T cells and a reduction in cells expressing CXCR4 were observed in REM patients, while RED patients showed a greater loss of cells expressing CCR5.Our findings do not support a role for reduction in activated T cell subsets to explain the greater maraviroc-induced immune recovery. Reduction in CXCR4CD4 and higher expression of CCR5CD4 T cells might represent a potential protection from non-R5 tropic viral strain overgrowth.